Market Place
Sourcing Support
FDA Approves First Biosimilar to Lucentis
03 Aug 2022 //
CONTRACTPHARMA
Teva Receives Approval for First Ophthalmology Biosimilar in Europe
20 May 2022 //
LEXBLOG
FDA Accepts Review of Polpharma & Bioeq`s BLA of Ranibizumab
04 Oct 2021 //
BUSINESSWIRE
Bioeq has submitted a BLA to the FDA for the ranibizumab biosimilar
06 Aug 2021 //
BUSINESSWIRE
Polpharma & Bioeq Joint Venture Submission of Biosimilar Ranibizumab BLA to FDA
06 Aug 2021 //
BUSINESSWIRE
Formycon & Bioeq announce submission of the BLA for FYB201
05 Aug 2021 //
PRESS RELEASE
Formycon and Bioeq Submitted marketing authorization application for FYB201
29 Jun 2021 //
FORMYCON
Bioeq Announces Coherus as Marketing for Its Biosimilar to Lucentis®
06 Nov 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.